Physician profile
Eduardo Demondesert
NPI 1386675536
$12,955.80
in general payments reported to CMS, 2019-2025
34 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,737 · 2020: $1,102 · 2021: $2,145 · 2022: $2,409 · 2023: $1,944 · 2024: $1,812 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,515 · Education: $47.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,515.18 |
| Education | $47.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,584.08 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,560.77 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $1,245.33 | 2019-2025 | |
| Janssen Biotech, INC. | $1,179.58 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $768.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $756.43 | 2019-2025 | |
| Boston Scientific Corporation | $611.14 | 2019-2025 | Exalt Model D, Resolution Clip |
| Celgene Corporation | $304.47 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $232.19 | 2019-2023 | Sutab, Suflave |
| Allergan, INC. | $175.46 | 2019 | |
| Nestle Healthcare Nutrition INC. | $174.00 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $171.01 | 2022-2025 | Dupixent |
| Genzyme Corporation | $131.93 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $128.15 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $124.95 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $124.39 | 2019-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $119.11 | 2025 | Iqirvo |
| Qol Medical, LLC | $93.14 | 2022-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $79.51 | 2020-2024 | Dificid |
| Ucb, INC. | $59.44 | 2019-2020 | |
| Celltrion USA INC. | $59.30 | 2024-2025 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $45.73 | 2024-2025 | Ibsrela |
| Cook Medical LLC | $32.80 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $29.22 | 2024 | Voquezna |
| Medtronic, INC. | $28.72 | 2023 | Interstim |
| Redhill Biopharma INC. | $27.87 | 2021 | |
| Madrigal Pharmaceuticals | $19.05 | 2025 | Rezdiffra |
| Mauna Kea Technologies, INC. | $18.35 | 2019 | |
| Lilly USA, LLC | $13.57 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $13.49 | 2022 | |
| Medtronic USA, INC. | $13.09 | 2019 | |
| Neurocrine Biosciences, INC. | $11.73 | 2022 | |
| Endo Pharmaceuticals INC. | $11.06 | 2019 | |
| Vivus LLC | $8.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Demondesert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.